• FuelPositive Corp. is a Canadian-based clean energy solutions innovator developing a means of using green ammonia as a non-carbon polluting fuel
• The company was recently featured in a broadcast by NetworkNewsAudio (“NNA”) that highlights FuelPositive’s advances in making green ammonia more portable, more cost-efficient and ultimately more power generating than environmentalist darling hydrogen
• The broadcast notes that traditional ammonia production typically creates significant pollution, but that the key advantage of FuelPositive’s Phase 2 Hydrogen-Ammonia Synthesizer is that it eliminates the pollution factor and makes carbon free ammonia easy to produce where needed as a transportation fuel
• The broadcast highlights the results of FuelPositive’s decision to commission a study of Canada’s off-peak green electricity capacity, showing that the country has sufficient energy to utilize green ammonia as a carbon-free fuel for all of Canada’s passenger and commercial freight needs

The dedication of Canadian-based FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) toward building renewable energy technology through manufacturing, licensing, partnership and acquisition opportunities, is the focus of a recent audio broadcast featuring news about FuelPositive’s decision to commission an analysis of Canada’s green off-peak electricity capacity, measuring the Canadian transportation sector’s fuel needs and carbon emissions. The NNA broadcast notes that ammonia produced in a carbon-free manner can provide fuel for commercial and public transportation and do it in a way that promotes responsible climate policy. “Many people don’t know it, but planes, trains, ships, trucks and other vehicles can be converted to run on ammonia – just as easily as they can be converted from gasoline and diesel to run on propane”, FuelPositive CEO Ian Clifford states in the news release about the broadcast (https://ibn.fm/FEOjZ). “The transportation sector just didn’t see a benefit to switching to ammonia until now, because the production of traditional ammonia results in massive carbon emissions. But, when you use our carbon-free NH3 made from green electricity rather than traditional ammonia, it means we can move people around and transport goods with no pollution.” In addition, ammonia presents advantages over the generally preferred green energy solutions that rely on hydrogen. Hydrogen can be stored physically as either a gas or a liquid, however the storage and transportation process is complicated because such storage typically requires high-pressure tanks and cryogenic temperatures. Therefore, improvements in the technology necessary to store and transport hydrogen are generally considered key to advancing its use as a renewable solution (https://ibn.fm/om7zd). Ammonia, however, is easy to store and transport using existing infrastructure. Its chemical symbol, NH3, is often referred to as hydrogen nitride instead of ammonia in recognition of its nitrogen and three hydrogen atoms. That structure makes ammonia the ideal carrier for hydrogen — in addition to the portability of FuelPositive’s technology, the end user can convert the green ammonia back to its hydrogen element to be used to produce electricity in a hydrogen fuel cell. It’s also much less expensive to manufacture carbon free ammonia than pure hydrogen by volume, according to the company. FuelPositive’s carbon-free production process also eliminates fertilizer-related carbon emissions in the agriculture sector. Currently, the agriculture industry remains the largest user of ammonia. Over 80 percent of traditional ammonia is used as fertilizer. The analysis by emissions reduction and carbon credit specialist Andre Mech that FuelPositive commissioned found that Canada has enough off-peak green electricity to produce carbon free ammonia to fuel 63 percent of all the passenger cars, light trucks, passenger aviation, buses, light rail, motorcycles, freight trucking, freight aviation, rail, marine and other sector vehicles in the country using non-polluting, carbon-free NH3 as a fuel. The analysis also found that Canada has enough off-peak green electricity to produce carbon free ammonia to fuel 100 percent of the passenger and commercial freight needs of its industries. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Fan Pass releases new offering exclusively for independent artists seeking next-level advantage in analytics, exposure, merchandise sales and overall streaming revenue
• The Company’s Pro services offer artists the opportunity to gain access to basic, standard, and premium logo, merchandise, and marketing services for a fee
• Streaming gear is available for purchase for artists on the platform to further enhance their craft using high quality equipment
• Fans can sign up to gain access to their favorite artists for a monthly fee – offering VIP access to live stream events and behind-the-scenes access

Currently at the heart of its 120-day plan, Friendable (OTC: FDBL), a mobile technology and marketing company focused on developing and identifying products, services, and brand opportunities, is increasing its offering to artists joining the Fan Pass platform with pro services and streaming merchandise. Artists can sign up for the livestreaming platform for free, host live performances for fans, and earn revenue for the sales they gain on the platform. With the release of the Fan Pass version 2.0 and the Artist Pro offering being tested for independent artists using the platform, CEO Robert A Rositano, Jr. stated “As we are onboarding new artists to the Fan Pass version 2.0 platform, it’s the ideal time to deliver additional support services to any artist who feels big labels aren’t for them and who wants to find an alternative way to get heard, get known and get paid. Delivering this capability to the artists on our platform is what Fan Pass is all about” (https://ibn.fm/FhiEV). The current selection of streaming gear is available through the Fan Pass store online. Equipment available online includes amplifiers, tripods, wireless microphones, and other high-quality items that every artist joining the platform needs to perfect their art. Those who sign up for the newsletter will receive an additional discount with their first purchase. Artists can use their new gear to make the best quality music videos and live streamed events to increase revenue potential. The user feedback from the Artist Pro structure will provide Friendable with more forward-thinking marketing strategies, which is aimed toward providing users with:

• The activation and set up of a merchandise store
• Custom merchandise designs (includes initial merchandise design)
• VIP all-access subscription to Fan Pass platform and content
• Promotion of all scheduled artist events
• Advanced analytics and fan data access, reported directly through the artist’s dashboard

This is available for the low rate of $8.99 per month. Along with the streaming gear, Friendable offers a premium line of pro services to help advance artists and their careers. These pro services include logo, merchandise, and marketing categories – in basic, standard, and premium formats. Each category provides artists access to quality logos, merchandise, and marketing materials made for their music and brand. Artists also make revenue on the merchandise they sell through the Fan Pass store. These are all a part of the digital media campaign being rolled out for artist and fan acquisitions by the company. The goal is to show artists, and fans alike, that the brand is one that can be trusted as a long-term partner while still extending the reach for new revenue growth opportunities. The Artist Pro platform is just one of the ways that Friendable is delivering their commitment to artists and fans in a tangible way, as pointed out by Rositano Jr. in an interview. He also pointed out that it is through these new offerings on the platform that the company is able to share achievements with artists, fans, the Friendable team, and its shareholders. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• New Sagitta electric vehicle will be unveiled at Nov. 17 LA Auto Show
• Imperium is CMW’s primary Sagitta distribution partner; company anticipates high demand for game-changing vehicle
• Limited production planned by late 2022, reservations accepted mid-year

DSG Global (OTCQB: DSGT) and its subsidiary, Imperium Motors, have announced the planned unveiling of the Sagitta(TM) electric vehicle during the upcoming Nov. 17, 2021, LA Auto Show (https://ibn.fm/3R6GE). Imperium will partner with California Mobility Works (“CMW”) to show the new three-wheel, four-passenger EV, which is expected to create quite a stir during the shows. “We are thrilled to team up with CMW and make Sagitta a huge success,” said Rick Curtis of Imperium Motors. “As a company focused on the EV market for many years, we are very confident that this vehicle will be a big winner.” Imperium is CMW’s primary Sagitta distribution partner, and the company anticipates high demand for the vehicle as well as a need for downstream partners to meet that demand. The innovative vehicle features superb styling and engineering and is designed to set a new standard for aesthetics, passenger and cargo space, range, and value. Sagitta will also showcase new technology that allows easy configurability and a wide range of owner-defined interior features. In addition, the vehicle should dramatically expand the accessibility of environmentally responsible EV technology to a broad range of consumers. “I am very excited to roll out this incredible new vehicle, which is not only a breakthrough in value for the EV market, but it is a thing of beauty and people will be pleasantly surprised by many innovations in the design,” said CMW cofounder and chief designer Jim Shook. Following the Nov. 17 unveiling of the Sagitta, CMW will begin initial testing and validation of the vehicle. The company anticipates limited production by late 2022 and will start accepting reservations for the vehicle sometime next year. “Jim and his team have done a remarkable job with Sagitta, which by the way means arrow in Latin,” said CMW chair Scott Burton. “And as an EV enthusiast, I am totally confident in the product and the immediate and continued success it will have in the market.” Founded in 2018 with the main objective of designing and manufacturing EVs, CMW is focused on transforming the EV market by providing world-class electric vehicles specifically designed to expand and accelerate the already fast-growing space. With an end goal of becoming a leading EV company within five years, CMW is committed to delivering superior value without sacrificing style, performance or safety. The company was founded by several luminaries of Silicon Valley including Kamal Consaga, Bobby Rekhi and Jim Shook. Imperium Motor Company is an ideal partner for CMW. An expert in EV sales, marketing and distribution, Imperium offers an impressive array of EV vehicles with emphasis on great design, a green mindset, performance, and functionality. Imperium vehicles include high-speed, mid-speed and low-speed electric vehicles, including cars, trucks, SUVs, vans, e-bikes, buses and scooters. “The addition of CMW to IMC’s list of OEM partners is a win-win scenario,” the company stated, “as it will greatly strengthen IMC’s product offering, while IMC represents a ready-made distribution and service organization for CMW-designed products.” DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch-screen engagement and electric golf carts under the Vantage Tag Systems (“VTS”) brand, the company is moving quickly with road-ready electric vehicles sold through its Imperium Motor Company subsidiary. For more information, visit the company’s website www.DSGTGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT

• $58.5 million in Adjusted Sales for first six months of 2021
• The company also reported repaying approximately $18 million of debt and restructuring over $20 million into a long-term debt
• Q2 also marked RWB’s acquisition of Acreage Florida, as well as an operational 45,000 SF greenhouse within the state, which it projects, will begin harvesting in Q4 2021
• RWB’s CEO expressed his optimism about the company’s performance in the Q3 and the second half of the year, given the strides made and the momentum realized in Q2

On August 30, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) released its financial results and subsequent events report for the second quarter of the 2021 fiscal year (“Q2, 2021”). While making the announcement, Brad Rogers, the Chairman and Chief Executive Officer (“CEO”) of the company, expressed his optimism about the company’s performance in Q3 and the second half of the year, owing to the strides made by the company, and the momentum realized in Q2. Key takeaways from the announcement included the company’s Q2 13% increase in revenue over the first quarter of the year. It is noted that there were significant raw material inventory purchases over that period, in support of growth for Q3 and anticipation of new branded product launches later down the line. Adjusted sales for the first six months of the 2021 fiscal year totaled $58.5 million, with revenue for Q2 totaling $13.3 million, up from $11.8 million in Q1 2021. The gross margin (excluding adjustments for biological assets) was $9.5 million for Q2 2021 (https://ibn.fm/esKgg). In addition to a growth in revenue, RWB also received the Florida Department of Health, Office of Medical Marijuana Use approval and closed the acquisition of Acreage Florida. Acreage Florida is a company that is licensed to operate medical marijuana dispensaries, a processing facility as well as a cultivation facility within the state of Florida. The transaction would see RWB possess a 114,000 SF facility for cultivation and a 4,000 SF freestanding administrative office building located on 15 acres in Sanderson, Florida. “In Florida, after closing the acquisition at the end of April, we have made strategic investments that are allowing us to quickly ramp up capacity as well as complete construction for new store openings before the end of 2021,” noted Mr. Rogers. Q2 2021 also saw RWB secure 20 double wide fully enclosed cultivation pods that will offer approximately 19,000 square feet of turn-key cultivation space. These pods will also provide 14,400 SF of canopy capable of producing over 7,000lbs of flower every year. RWB also announced having completed the more comprehensive portion of Michigan’s two-step application process for medical marijuana licensing through its wholly-owned operating subsidiary, RWB Michigan, LLC. Additionally, by the close of Q2 2021, RWB had completed over $52 million in financing transactions, retiring at least $7.7 million in debt. The company also closed the acquisition of an operational 45,000 SF greenhouse located on 4.7 acres of land in Apopka, Florida. It projects that the facility will be ready for harvest by Q4 2021. RWB also exercised its option to extend the maturity of its Credit Facility to January 2022, with an option to further extend it to July 2022. In total, over the Q2 2021 period, approximately $10 million of debt was retired, with additional agreements to restructure $20 million of debt, expected to close over the first week of September 2021, and with the maturity date moved to January 2023. RWB is a first-mover, an industry leader in American cannabis. It is driven by becoming the prominent and most recognizable cannabis company in the United States (“US”). It is proud of its ethical, manufacturing, branding, educational and employment standards, the highest in the industry. Since its inception, the company has positioned itself as one of the top three multi-state operators in cannabis and hemp-derived product lines within the US market. Headquartered in Vancouver, RWB has made significant investments within the US and has pending acquisitions in Michigan, and Massachusetts, with plans to enter California at scale. The company plans to create the first-ever standardized cannabis facility in the US to ensure superior quality. For its operations in Michigan, RWB uses a 3rd party licensee. The licensing agreement specifies that the revenue the company can recognize is product sales, less direct expenses, and inventory purchases. Consequently, RWB’s revenue in Michigan is always understated. Still, the company has managed to post impressive results, which make its future look promising. Q2 2021 was remarkable for RWB. Fiscal performance was impressive, and the company also made some strategic decisions and investments that guarantee its growth in performance as time progresses. The company is confident and optimistic about its performance in Q3 as well as the second half of 2021, all stemming from the progress and the momentum achieved from Q2. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• Mind Cure Health Inc. CEO Kelsey Ramsden was featured in a recent Bell2Bell podcast interview, during which she explained the company’s primary focal points – digital therapeutics and drug development
• On the digital therapeutics side of its business, the company is developing iSTRYM, a clinical-grade, evidence-backed, science-based, AI-driven tool for both therapists and patients, scheduled for full commercial launch in Q1 2022
• MCUR has successfully synthesized the chemically complex ibogaine and intends to scale up its production during the remainder of 2021

As a diversified life sciences company at the forefront of the mental health industry, Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) actively develops technology, conducts research, and distributes products. According to company President and CEO Kelsey Ramsden, who was featured in a recent Bell2Bell podcast (https://ibn.fm/dyDt5), its two focal points are digital therapeutics, focusing on psychedelic therapy, and drug development, leaning toward psychedelic molecules. When the company was developing its model and go-to-market strategy, it considered the regulation and timing of regulatory change instead of solely focusing on clinics and molecules. This positions the company to align with changes at the government level unlocking some of the psychedelic molecules. “What that meant for us was investigating molecular research that would be the blue-sky horizon, so, independent of when the typical generic MDMA or Psilocybin get approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development,” stated Ramsden. On the digital therapeutics end, Mind Cure Health is developing a clinical-grade, evidence-backed, science-based, AI-driven tool, known as iSTRYM, for therapists deploying psychedelic assisted therapy in clinics. iSTRYM, which modernizes care, is also meant to help patients have an app that supports them through their care, resulting in better outcomes, shorter patient timeframes in clinic, and approval and unlocking insurance payments for psychedelics. Once dismissed as trifles of counterculture, psychedelics are now being held to a higher regard. This is largely due to revelations, through research, that they can be used to treat mental health conditions such as depression, drug dependency, PTSD, and more. However, according to a New York Times article, they are yet to receive mainstream acceptance despite the ongoing scientific work to change this (https://ibn.fm/ffIQo). This is perhaps due to stigma and the old view people may still have of psychedelics, which is why podcast host Stuart Smith sought to find out how the company intends to deal with this hurdle. “I do think we do have some of these hurdles to overcome, but, at the same time, with tools like digital therapeutics and research-backed psychedelics, I think we overcome some of the stigma with science,” Ramsden explained. So far, in 2021, MCUR has reached some key milestones, including raising $23 million in a bought deal short form prospectus public offering that closed in February this year (https://ibn.fm/BJH9h). On the technology side, MCUR launched the minimum viable product (“MVP”) of iSTRYM in Q3 2021. On the drug development and research side, the company synthesized ibogaine and has launched the second stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. The company has also filed patent applications for two routes of chemical synthesis of ibogaine. “Ibogaine comes from the iboga root out of Africa. It’s a psychedelic drug and is very complex chemically, very difficult to build in the lab fully chemically synthesized, which is what we need to get stability and normalcy so that we can meet FDA regulations. And our team successfully synthesized ibogaine – the full chemical synthesis,” Ramsden continued. When asked about the company’s plans for the remainder of 2021, the company intends to spend about six months iterating the iSTRYM product in anticipation of a full commercial product launch in Q1 2022. Mind Cure Health also aims to scale up its ibogaine production to provide the psychedelic drug to researchers. Further, it is working on new research initiatives, to be announced in due course. For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• RYAH releases report outlining ways cannabis is being used to treat conditions associated with HIV and AIDS
• Report data compiled by RYAH Data Ecosystem between January 1, 2018, and August 26, 2021
• Data includes specific HIV and AIDS conditions, details cannabis strains used by patients
• Three-part RYAH Data Ecosystem includes volume control and management devices, QR tracking to identify product formulations and parameters, mobile apps to manage information and provide feedback

With a mission to advance remote-health solutions and analytics-based patient treatments across the world, RYAH Group (CSE: RYAH) (formerly RYAH Medtech) is the leader in volume control and management technology for plant-based medicine. The company recently released a report outlining cannabis treatment options to address symptoms and conditions associated with HIV and AIDS. The report, titled “Cannabis Use For Conditions Associated With HIV and AIDS”, is based on data compiled by the RYAH Data Ecosystem between January 1, 2018, and August 26, 2021. Through the RYAH Data Ecosystem, patients were able to submit data outlining symptoms they addressed with the use of cannabis, in addition to detailing specific cannabis strains used to treat those conditions. Some of the conditions logged and analyzed by the RYAH Data Ecosystem included fatigue, cachexia (a disease characterized by loss of muscle mass), mental health issues, wasting syndrome, chronic pain, hepatitis C, nausea, and inflammation. Along with providing gender-specific details on the conditions experienced by users, the report also includes critical information on the diverse range of cannabis strains used by patients to treat each condition. The ground-breaking report is part of RYAH’s data-driven mission to provide innovative plant-based medical treatments that leverage the use of loT (Internet of Things) dose-measuring devices and AI analytics applications. With a focus on collecting and building AI-powered data models, the company’s three-part ecosystem is designed to manage volumetrics and capture pertinent data in order to provide innovative plant-based medical treatments tailored to each patient. Each segment of RYAH’s Data Ecosystem builds upon the company’s goal to generate a flow of information that is critical to building AI-powered models that enhance treatment administration. The first section focuses on providing precision volume control solutions with the RYAH Patch, Inhaler, and Liquid Dispenser. The second segment leverages a QR tracking application to track product formulations and volume control parameters. The final segment features RYAH’s mobile applications that patients can use to provide feedback via their smart devices. With a focus on predictive analytics in the global medical plant and nutraceutical intake industry, RYAH is dedicated to helping doctors and patients leverage the power of data to personalize plant-based treatments for better patient outcomes. Bolstered by a robust intellectual property portfolio and suite of portable, cost-effective products, the company is positioned to lead the industry in volume control and management technology for plant-based medicine. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• On September 7, 2021, Mr. Fred Leigh was appointed as director and Executive Chairman of PlantX’s Board of Directors, effective immediately
• Mr. Leigh previously chaired the company’s Advisory Board, which has since been dissolved
• PlantX looks forward to leveraging on Mr. Leigh’s expertise, knowledge and over 40 years of experience in capital markets to help steer the company
• Mr. Leigh’s appointment follows PlantX’s move to expand its market reach and grow its overall market presence

On September 7, 2021, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) announced the appointment of Mr. Fred Leigh as a director and Executive Chairman of the company’s Board of Directors, effective immediately (https://ibn.fm/BThVn). Mr. Leigh’s appointment follows PlantX’s move to grow its market presence and overall market reach. This is marked by its investment in e-commerce, along with product diversification, as seen with its alcoholic beverage line (https://ibn.fm/RWdRz). The company looks to capitalize on Mr. Leigh’s expertise in the industry, along with his knowhow to steer the company forward and help achieve even bigger and more ambitious goals in the future. While confirming his appointment, Mr. Leigh noted: “I always look to be involved in scalable business models with potential, a focused vision and dedication to making a positive difference. I enjoy working along with strong founders who are dedicated, passionate and fully committed to their work.” He further added: “With Sean Dollinger as the relentless founder and the amazing PlantX team, I am honored to act and serve as Executive Chairman of PlantX.” Mr. Leigh previously served on the company’s Advisory Board. Additionally, he has over 40 years of experience in capital markets. Mr. Leigh has also founded and served in key executive roles within various companies that have since gone public. With his appointment as PlantX’s Executive Chairman, the company trusts that Mr. Leigh will offer leadership and lend the knowledge that he has gained over his years in the industry. The Advisory Board, which Mr. Leigh previously chaired, has since been dissolved. PlantX’s management noted that his appointment as Executive Chairman would mitigate the effects of this dissolution while also offering additional cost savings for the company. Mr. Leigh joins the rest of PlantX’s Board of Directors, including Lorne Rapkin, Peter Simeon, Quinn Field-Dyte, Ralph Moxness, and Alex Hoffman. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• U.S.-based data tech company FingerMotion is focused on the market potential of Chinese companies’ need for rich communication services (“RCS”) and big-data insights
• FingerMotion has been particularly focused on the insurance industry’s need for data analysis in recent months, particularly in light of China’s early-stage structure for credit and risk assessment among consumers
• FingerMotion’s Sapientus platform provides predictive services for risk assessment, spawning a landmark agreement with Pacific Life Re-insurance’s insurtech solutions in China
• Because China regards insurance as compulsory for sectors such as pension protection, medical care, job hazards, unemployment and maternity care, the potential for insurance services is high in a country that boasts the largest population on the planet

China-focused communications technology company FingerMotion (OTCQX: FNGR) is using big data and analytical technology to provide its clients with market insights as a growing number of Chinese consumers adopt online insurance products. Last year, online insurance premiums surpassed 290 billion yuan (US$44.8 million) in the country, according to the Google translation of a Gold Investment Network insurance news release (https://ibn.fm/7g2lO). The popularity of online premiums among consumers fueled a rapid surge in new economic activity within the country that continues on an upward path as businesses turn to big data, cloud computing, artificial intelligence (“AI”), and other value-added technology to accelerate their revenues (https://ibn.fm/IDXw7). FingerMotion has seen its revenues grow in consecutive reporting quarters during the past year (https://ibn.fm/Yg42v) and is anticipating further success thanks in part to a landmark agreement with Pacific Life Re-insurance that effectively positions FingerMotion as Pacific Life’s data provider, utilizing FingerMotion’s trademarked Sapientus platform. Pacific Life is one of the world’s top five Insurance companies, well into its second century with $1.1 trillion in life insurance policies and $171 billion in assets (https://ibn.fm/DYI95). The company is on a trajectory to firmly bring its services ashore among China’s world-leading population, where consumers are required to carry social insurance and certain types of commercial insurance. Social insurance covers basic insurance policies for pensions, medical care, on-the-job injuries, unemployment, and maternity care, among other things. The China Banking and Insurance Regulatory Commission (“CBIRC”) is responsible for oversight of insurance and re-insurance regulation, and foreign companies must meet conditions for CBIRC’s approval (https://ibn.fm/gFBMF). Because China’s credit and insurance risk standards are still in a nascent stage, the predictive solutions offered by FingerMotion’s analytical technology and its big consumer data access provide clients such as Pacific Life a means of anticipating their risks with policy holders. The predictive services of FingerMotion’s Sapientus database are focused on the insurance industry, but may yet become integral to solutions in other industries as well, such as in varied health care, financial services and consumer e-commerce sectors. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Flora closed a €2 million investment in Hoshi International Inc., fulfilling the earlier-announced LOI back in June 2021
• This move is set to capitalize on Hoshi’s strong European presence, its technical know-how along with its understanding of the European market
• Hoshi acknowledged the investment with the announcement that it would work together with Flora to bring to market finished product formats from Flora’s brand portfolio
• Flora referred to this investment as the first of many steps by the company to advance its plans to launch products across the world

On August 24, 2021, Flora Growth (NASDAQ: FLGC) announced closing a €2 million investment in Hoshi International Inc. It also announced that it had increased its fully-diluted ownership in Hoshi through a securities swap. When making the announcement, Luis Merchan, the President and Chief Executive Officer (“CEO”) of Flora, noted: “We are excited to increase our alignment with the Hoshi management team and believe the partnership will be much greater in scope than only using their Portugal and Malta facilities as a European importation gateway for our Colombian cannabis flower and derivatives” (https://ibn.fm/pTzKf). Earlier in June this year, Flora had announced signing a Letter of Intent (“LOI”) for planning to make an initial strategic equity investment into Hoshi. Flora termed this as “the first of many steps to advance its plans to launch Flora-branded products across the world” (https://ibn.fm/B9K8x). Having followed through with the investment, the company is now set to capitalize on Hoshi’s strong European presence. It is also bound to leverage the latter’s technical know-how, along with its understanding of the European market, to not only expand its market reach but also obtain its European Union Good Manufacturing Practices (“EU-GMP”) certification. John Aird, the CEO of Hoshi, noted: “We are excited to begin working alongside the Flora team and sharing our understanding of the European market while working together to bring to market finished product formats from Flora’s brand portfolio that are suitable for European medical consumers. He further added: “Not only has Flora made an investment into Hoshi, but through our securities swap, the Hoshi management team also has a vested interest in the success of Flora Growth and our long-term working relationship.” Flora’s €2 million investment came with the following terms:

• Flora would hold a right of first refusal to supply any cannabis oil or derivative products acquired by Hoshi or any of its affiliates at the processing facility in Malta. This will be subject to the parties entering into a definitive agreement by October 1, 2021
• Flora would be Hoshi’s preferred supplier of genetic material and finished cannabis derivative products at its cultivation and processing facility in Portugal, subject to the two parties entering into a definitive agreement by October 1, 2021
• Flora would be entitled to nominate one Director to Hoshi’s Board of Directors, specifically Luis Merchan, Flora’s President and CEO
• Hoshi will use commercially reasonable efforts to grant Flora access to its EU-GMP auditors to assist Flora to obtain EU-GMP certification at its Cosechemos cultivation and extraction facility in Colombia

Hoshi is a fully integrated cannabis company that focuses on the European market. Its team comprises renowned cannabis entrepreneurs, hence its focus on developing and operationalizing assets across the global cannabis industry. Hoshi’s focus and emphasis are on cultivating, manufacturing, and distributing cannabis products throughout the EU. So far, the company is uniquely positioned to become the leading provider of cannabis and derivative products for this budding European market. On the other hand, Flora is a cannabis cultivator, processor, and brand builder with a focus on the international market. It has made a name for itself by leveraging natural and cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including pharmaceuticals, hemp textiles, cosmetics, and food and beverage. Flora currently operates one of the world’s most extensive outdoor cultivation facilities, intending to market a higher-quality premium product at below-market prices. 2020 was a big year for the European medical cannabis industry. Germany’s imports of certified flower for medical purposes reached 9,231 kg, according to the Federal Institute for Drugs and Medical Devices. Between January and September 2020, the value of medical cannabis transactions in Germany alone amounted to €111 million, with flower sales accounting for 48.6% of these sales. Prohibition Partners has even projected that by 2024, over one million German patients will have access to medical cannabis, making Germany the leading European cannabis market in terms of growth. It is further projected that the German medical cannabis market will be worth €7.7 billion by 2028. By the end of 2021, it is estimated that the entire European cannabis market will be valued at €403.4 million. By 2025, this industry is set to be valued at €3.2 billion, representing a compound annual growth rate (“CAGR”) of 67.4% between 2021 and 2025. Flora hopes to capitalize on Hoshi’s understanding of and presence within the European market to capitalize on its strategic growth plans. Closing this investment is a step in the right direction and a first in Flora’s overall expansion plan to venture into the European market for its cannabis products. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments
• Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes
• The DehydraTECH technology enhances the delivery of pharmaceuticals that can be administered orally, and testing has shown no adverse chemical compounds have been created in the process
• The COVID-19 pandemic has raised the profile of the anti-viral medication market, enhancing the opportunities for Lexaria’s revenue stream

As life sciences technology innovator Lexaria Bioscience (NASDAQ: LEXX) takes a leap forward in R&D programs demonstrating the effectiveness of its trademarked oral substance delivery platform, the company is preparing to join other participants in the 23rd annual Global Investor Conference hosted by full-service investment bank H.C. Wainwright & Co. The investor conference scheduled Sept. 13-15 will be a hybrid online and in-person gathering of companies enjoying opportunities for platform presentations, one-on-one meetings with investors, and networking with other attendees (https://ibn.fm/TiS8V). Lexaria’s CEO, Chris Bunka, will be making the company’s presentation, which will be available to attendees on Monday September 13th. Lexaria’s recent strides in developing and testing its oral delivery platform DehydraTECH include its successful 2021 antiviral drug program, which has produced data showing DehydraTECH can enhance antiviral drugs’ ability to reach the bloodstream so that they can safely and more effectively do what they are designed to accomplish. DehydraTECH processed substances such as pharmaceutical drugs enhance their bioavailability, and the clinical trials have also demonstrated that DehydraTECH does not alter nor degrade the drug molecules chemically as to create new molecular entities (“NMEs”) that would create new regulatory concerns for the finished products (https://ibn.fm/VWWld). H.C. Wainwright has a history of leading investment transaction volumes ranked by market research service PlacementTracker. Wainwright has consistently placed first among investment banks for confidentially marketed public offerings, registered direct and private placement transactions, according to the analysts (https://ibn.fm/lG6DA). The September event will include a panel discussion with former Food and Drug Administration Commissioner Scott Gottlieb (2017-2019), who is a member of the board of directors of drug maker Pfizer, Inc., and is preparing to roll out his long-awaited book, “Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic,” this month. The antiviral medication market has gained particular attention during the ongoing COVID-19 pandemic, and Lexaria’s DehydraTECH is in a position to potentially bring in significant revenues in partnership with the antiviral medications as well as NSAIDs and products that target hypertension and alternative nicotine products — an opportunity the company has been mindful of. The potential for using DehydraTECH in conjunction with cannabidiol (“CBD”) to target hypertension is one of the sectors of Lexaria’s research gaining attention following the results of a recent study showing DehydraTECH-processed CBD generated a rapid and sustained drop in blood pressure among study participants (https://ibn.fm/AZQYS). “Lexaria was also pleased that its DehydraTECH-CBD was well tolerated by all subjects, with no serious adverse events or side effects observed or reported. Ingestion of the concentration-matched, generic CBD control, on the other hand, resulted in unwanted side effects in some of the volunteers,” the company’s news release states. “These findings corroborate what Lexaria has previously evidenced in other unrelated studies whereby human volunteers have also experienced reduced side effects with DehydraTECH-processed test articles compared to concentration-matched, generic controls.” A second human clinical hypertension study of DehydraTECH’s capabilities is under way, and a third study is planned this year once the results of the first two studies are carefully evaluated and considered. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX